An Analysis of Recent FDA Oncology Scientific Publications
The Oncologist is a journal devoted to medical and practice issues for surgical, radiation, and medical oncologists.
Related Articles
FDA approves brentuximab vedotin with lenalidomide and rituximab
On February 11, 2025, the FDA approved brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in combination with lenalidomide and rituximab.
FDA approves brentuximab vedotin with lenalidomide and rituximab
On February 11, 2025, the FDA approved brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in combination with lenalidomide and rituximab.
FDA approves brentuximab vedotin with lenalidomide and rituximab
On February 11, 2025, the FDA approved brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in combination with lenalidomide and rituximab.
FDA approves mirdametinib for adult and pediatric patients with neurof
On February 11, 2025, the Food and Drug Administration approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients 2 years…
A Unified Approach to Health Data Exchange
This Special Communication outlines the ways in which the US Department of Health and Human Services has worked to use electronic health record data to…
OCE ENGAGE: A Project Community Newsletter
A quarterly newsletter for patients living with cancer, survivors, advocates and consumers
FDA approves sotorasib with panitumumab for colorectal cancer
On Jan. 15, 2025, the FDA approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for KRAS G12C-mutated metastatic colorectal cancer.
OCE Conversations on Cancer – Introducing Project Connect: A World-Wide Forum for Patients with Cancer
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy
Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology